This Document can be made available in alternative formats upon request

REVISOR

н. **F.** No. 2056

State of Minnesota

HOUSE OF REPRESENTATIVES

03/09/2021 Authored by Howard, Bahner and Bierman

The bill was read for the first time and referred to the Committee on Commerce Finance and Policy 03/17/2021 Adoption of Report: Re-referred to the Committee on Health Finance and Policy

1.1	A bill for an act
1.2 1.3 1.4	relating to insurance; limiting co-payments for prescription drugs and related medical supplies prescribed to treat a chronic disease; proposing coding for new law in Minnesota Statutes, chapter 62Q.
1.5	BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:
1.6	Section 1. [62Q.481] CO-PAYMENTS FOR PRESCRIPTION DRUGS TO TREAT
1.7	CHRONIC DISEASE.
1.8	Subdivision 1. Co-payment limit. A health plan that imposes co-payments on the
1.9	coverage of prescription drugs must limit the amount of any co-payment to \$25 per
1.10	one-month supply for prescription drugs prescribed to treat a chronic disease and related
1.11	medical supplies necessary to administer the prescription drugs.
1.12	Subd. 2. Definition of chronic disease. For purposes of this section, "chronic disease"
1.13	means diabetes, asthma, and allergies requiring the use of epinephrine auto-injectors.
1.14	EFFECTIVE DATE. This section is effective January 1, 2022, and applies to health
1.15	plans offered, issued, and renewed on or after that date.

1